Martina Schatzl - Publications

T-Cell Engager-Mediated HLA Antibody Depletion before Kidney Transplantation.

Journal: The New England journal of medicine

Published: July 29, 2026

Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension.

Journal: The Lancet regional health. Europe

Published: March 30, 2026

The Effects of Clazakizumab on Peripheral Blood and Kidney Transcriptomes in Patients With Late Antibody-Mediated Rejection.

Journal: Kidney international reports

Published: July 22, 2025

CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation.

Journal: Expert opinion on investigational drugs

Published: February 10, 2025

Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort Study.

Journal: Transplantation

Published: October 15, 2024

Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: October 07, 2024

A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.

Journal: The New England journal of medicine

Published: May 28, 2024

Natural Killer Cell Presence in Antibody-Mediated Rejection.

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Published: April 30, 2024

Diagnosis and treatment of COVID-19 in intensive care units

Journal: Medizinische Klinik, Intensivmedizin und Notfallmedizin

Published: September 27, 2021